Background Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1
protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from …

A subcutaneous (SC) formulation has been developed for the humanized monoclonal
antibody (mAb) trastuzumab as an alternative to established intravenous (IV) infusion. The …

Nilotinib, an oral inhibitor of the tyrosine kinase activity of Abelson protein, is approved for
the treatment of patients with newly diagnosed chronic myeloid leukemia (CML) in chronic …

Purpose This two-stage phase IB study investigated the pharmacokinetics and safety of
subcutaneous (SC) versus intravenous (IV) administration of rituximab as maintenance …

This overview article describes the non-clinical pharmacology, pharmacokinetic and clinical
dose-finding programs supporting the development of a novel subcutaneous formulation for …

9051 Background: The MAPK and PI3K pathways share common upstream activators and
contribute to cell proliferation, differentiation, and survival. Due to compensatory signaling …

Chronic myeloid leukemia (CML) is rare in children and accounts for≤ 15% of all myeloid
leukemia cases. When we initiated this study with nilotinib, imatinib was the only tyrosine …

Background CGM097 inhibits the p53-HDM2 interaction leading to downstream p53
activation. Preclinical in vivo studies support clinical exploration while providing preliminary …

Aims The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to
investigate the pharmacokinetics and safety of subcutaneous (sc) rituximab compared with …

Asciminib, a first‐in‐class, Specifically Targeting the Abelson kinase Myristoyl Pocket
(STAMP) inhibitor with the potential to overcome resistance to adenosine triphosphate …